News for Affimed N.V. (AFMD)

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 200 points on Monday. Following the market opening Monday, the Dow traded dow...

Shares of Novavax, Inc NVAX rose sharply in today's pre-market after the FDA gave its conditional approval to its COVID-19 vaccine, targeting specific populatio...

U.S. stocks traded slightly higher this morning, with the Nasdaq Composite gaining around 0.2% on Friday. Following the market opening Friday, the Dow traded u...

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Tuesday. The Dow traded down 0.49% to 42,203.63 while th...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 250 points on Monday. The Dow traded down 0.20% to 42,323.48 while the NASDAQ ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

As of midday on Monday, April 7, 2025, U.S. markets continue to experience significant volatility following President Trump's sweeping tariff announcements

**media[576528]**

MANNHEIM, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. ( AFMD) (”œAffimed”, or the ”œCompany”), a clinical-stage immuno-oncology company com

After disclosing revised clinical results for its AFM24/atezolizumab combination treatment in non-small cell lung cancer, Affimed N.V. (AFMD, Financials) shares

Affimed (AFMD) stock plunged 23% after the company reported updated data from a clinical trial of AFM24/atezolizumab in the treatment of non-small cell lung cancer. Read more here.

New York-based Syntec Optics Holdings, Inc. (OPTX) is up over 167 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Affimed N.V. (AFMD), Tuesday announced the updated clinical results from the ongoing AFM24-102 trial, evaluating the AFM24/atezolizumab combination therapy in heavily pretreated non-small cell lung cancer or NSCLC patients.

AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest d

MANNHEIM, Germany, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. ( AFMD) (”œAffimed”, or the ”œCompany”), a clinical-stage immuno-oncology company comm

**media[486945]**

The combination of acimtamig with AlloNK® demonstrated an overall response rate of 86% and complete response of 55% in 22 heavily pretreated patients with R/R

Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed s

**media[484151]**